impact factor
logo
 

Full Papers

 

Major vault protein/lung resistance related protein: a novel biomarker for rheumatoid arthritis


1, 2, 3, 4, 5, 6, 7

 

  1. Department of Microbiology, National and Kapodistrian University of Athens, Greece.
  2. Rheumatology Clinic, Naval Hospital of Athens, Greece.
  3. Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
  4. Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
  5. Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
  6. Department of Microbiology, National and Kapodistrian University of Athens, Greece.
  7. Department of Microbiology, National and Kapodistrian University of Athens, Greece. jroutsias@med.uoa.gr

CER13575
Full Papers

purchase article

PMID: 33124564 [PubMed]

Received: 16/05/2020
Accepted : 07/09/2020
In Press: 29/10/2020

Abstract

OBJECTIVES:
Rheumatoid arthritis (RA) can lead to joint destruction and early institution of effective treatment can preserve joint function. Biomarkers can establish early diagnosis and predict effect of treatment. Vault particles, large cytoplasmic ribonucleoprotein particles that participate in inflammation, might serve as biomarkers. The aim of this study was to assess the diagnostic and the prognostic value of major vault protein (MVP) and their antibodies in RA.
METHODS:
Serum samples from 159 RA patients, 26 early RA (ERA) patients, 21 patients with osteoarthritis (OA) and 30 healthy individuals were tested for MVP, anti-cyclic citrullinated peptide (anti-CCP) and C-reactive protein (CRP) using enzyme-linked immunosorbent assays (ELISA). Rheumatoid factor (RF) was tested by nephelometry, and anti-MVP antibodies were detected by anti-MVP peptide ELISA using an in-house protocol.
RESULTS:
MVP levels were higher in RA and ERA, compared to OA and healthy controls (p<0.00001). A combination of MVP with RF or anti-CCP showed an improved diagnostic accuracy compared to RF or anti-CCP alone in RA and ERA. MVP exhibited similar AUC levels to anti-CCP and RF in RA whereas in ERA, MVP exhibited the same or slightly higher AUC levels, compared to anti-CCP and RF, respectively. High MVP levels were associated with lack of response to treatment. Levels of anti-MVP peptide 2 antibodies were significantly higher in RA compared to healthy controls (t= 2.73, p=0.007).
CONCLUSIONS:
MVP and autoantibodies against MVP may have the potential to serve as diagnostic and prognostic biomarkers in RA.

Rheumatology Article